SCHEMBL972274

SCHEMBL972274

Oc1[c]ccc2cccc(O)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MCL1 Q07820 2/20 0.45
DNMT1 P26358 1/20 0.45
CACNA1B Q00975 1/20 0.45
APBA1 Q02410 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
CDK2 P24941 3/20 0.38
HPGD P15428 5/20 0.38
HSD17B10 Q99714 5/20 0.38
TSHR P16473 4/20 0.38
MAPT P10636 4/20 0.38
ALOX15 P16050 4/20 0.38
CYP1A2 P05177 3/20 0.38
RECQL P46063 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
SNCA P37840 3/20 0.38
APP P05067 2/20 0.38
THRB P10828 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29212679 0.81 MEN1 (0.44) ALDH1A1MEN1KMT2AHPGDHSD17B10
SCHEMBL8019186 0.79 JAK2 (0.39) ALDH1A1HPGDHSD17B10TSHRALOX15
SCHEMBL5030641 0.79 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL70219 0.75 ALDH1A1 (0.62) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL29363189 0.75 ALDH1A1 (0.62) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL27581516 0.75 SOS2 (0.39) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL6633176 0.74 TTR (0.50) ALDH1A1MEN1KMT2ACDK2MAPT
SCHEMBL7126508 0.73 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL9115296 0.73 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AMCL1DNMT1
SCHEMBL5889014 0.71 GABRA1 (0.46) ALDH1A1MEN1KMT2AHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2885357-B1 INKS FOR INK-JET PRINTING FUJIFILM IMAGING COLORANTS INC (US) 2018-06-13 EP claimed
US-9540532-B2 Inks for ink-jet printing FUJIFILM IMAGING COLORANTS, INC. (US) 2017-01-10 US claimed
US-20150184013-A1 Inks for Ink-Jet Printing FUJIFILM IMAGING COLORANTS, INC. 2015-07-02 US claimed
US-20120306962-A1 INKS FUJIFILM IMAGING COLORANTS, INC. 2012-12-06 US claimed
US-7056376-B2 Printing process using specified AZO compounds AVECIA LIMITED (GB) 2006-06-06 US claimed
EP-1516021-B1 PRINTING PROCESS USING SPECIFIED AZO COMPOUNDS FUJIFILM IMAGING COLORANTS LTD (GB) 2006-05-17 EP claimed
US-20040020404-A1 Printing process using specified AZO compounds AVECIA LIMITED 2004-02-05 US claimed
US-20010041794-A1 Nucleotide analogs GILEAD SCIENCES, INC. 2001-11-15 US claimed
US-5798340-A ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY GILEAD SCIENCES, INC. (US) 1998-08-25 US claimed
US-20190345190-A1 PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2019-11-14 US disclosed
US-20190315785-A1 PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2019-10-17 US disclosed
EP-2885357-B1 INKS FOR INK-JET PRINTING FUJIFILM IMAGING COLORANTS INC (US) 2018-06-13 EP disclosed
US-9957225-B2 Treatment of friedreich's ataxia using histone deacetylase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2018-05-01 US disclosed
US-20180086784-A1 Phosphonate analogs of HIV inhibitor compounds GILEAD SCIENCES, INC. 2018-03-29 US disclosed
WO-1996026933-A9 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES 1996-11-28 WO disclosed
WO-1996033200-A1 NOVEL COMPOUNDS AND METHODS FOR THERAPY ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VED C^¿ESKÉ REPUBLIKY (CZ) 1996-10-24 WO disclosed
WO-1996026933-A1 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES GILEAD SCIENCES, INC. (US) 1996-09-06 WO disclosed
WO-1996023801-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1996-08-08 WO disclosed
EP-0719274-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1996-07-03 EP disclosed
WO-1995007919-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1995-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041794-A1 Nucleotide analogs PNP, NUDT1, TYMP ALDH1A1 4101/4885MEN1 1417/4885KMT2A 3460/4885
US-20190315785-A1 PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS PIK3CA, TYMP, ITPA ALDH1A1 4577/4885MEN1 3266/4885KMT2A 3041/4885
US-20190345190-A1 PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS PIK3CA, TYMP, ITPA ALDH1A1 4577/4885MEN1 3266/4885KMT2A 3041/4885
US-20180086784-A1 Phosphonate analogs of HIV inhibitor compounds PIK3CA, TYMP, ITPA ALDH1A1 4577/4885MEN1 3266/4885KMT2A 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.